Two clinician scientists from the Institute of Cancer Sciences have been appointed to chair exciting initiatives run by the National Cancer Research Institute (NCRI).

Dr Karin Oien, Clinical Senior Lecturer in Experimental Therapeutics, has been named as the inaugural chair of the Cellular Molecular Pathology initiative (CM-Path), which is tasked with boosting the UK’s research activity in the cellular and molecular pathology of cancer.

At the same time, Professor Anthony Chalmers, Chair of Clinical Oncology, has taken over the chair of the NCRI’s Clinical and Translational Radiotherapy Research Working Group (CTRad). Since its inception in 2009, CTRad has been hugely successful in increasing both the quantity and quality of radiotherapy research activity in the UK, having delivered a more than twofold increase in recruitment to radiotherapy clinical trials over the period and a similar increase in high impact scientific research outputs.

Reflecting this success, CM-Path has been built on the CTRad model and Dr Oien and Prof Chalmers are looking forward to working together both to enhance the UK cancer research environment and to consolidate the University of Glasgow’s status as one of the leading oncology research centres in the UK.

First published: 3 October 2016

<< October